Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Background Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. Objective We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. Methods Six consecutive patients with moderate to severe AD who had fa...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2015-09, Vol.73 (3), p.395-399 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 399 |
|---|---|
| container_issue | 3 |
| container_start_page | 395 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 73 |
| creator | Levy, Lauren L., MD Urban, Jennifer, MD King, Brett A., MD, PhD |
| description | Background Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. Objective We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. Methods Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. Results Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 ( P < .05) during 8 to 29 weeks of treatment. There were no adverse events. Limitations Small sample size, lack of placebo control group, and the possibility of bias are limitations. Conclusion The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD. |
| doi_str_mv | 10.1016/j.jaad.2015.06.045 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1705476667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962215018514</els_id><sourcerecordid>1705476667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-bf3db2709821be1aa5907b6e20f2253ab2c4857553b25ac6bdbde075b78b15c33</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhoMoznX0D7iQLN20nqRN0oIIMvjJgAvHdUjSU246bXNNUmX-val3dOHCVTjwvC_keQl5zqBmwOSrqZ6MGWoOTNQga2jFA3Jg0KtKqk49JAdgPVS95PyCPElpAoC-bdRjcsEl61sF8kCGm4gmL7hmGkYa0ZnZ-RxNuU0OJ-_ogHEx2Wef6E-fjzQfkYZoZvrZrFuit341Calfj976HCLNYTSlwq_e0t9VGZ-SR6OZEz67fy_Jt_fvbq4-VtdfPny6entdubZjubJjM1iuoO84s8iMET0oK5HDyLlojOWFE0qIxnJhnLSDHRCUsKqzTLimuSQvz72nGL5vmLJefHI4z2bFsCXNFIhWSSlVQfkZdTGkFHHUp-gXE-80A73b1ZPe7erdrgapi90SenHfv9kFh7-RPzoL8PoMYPnlD49RJ-dxdTj4ojbrIfj_97_5J-7m4rFscot3mKawxbX400wnrkF_3ffd52UCWCdY2_wClbihfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1705476667</pqid></control><display><type>article</type><title>Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Levy, Lauren L., MD ; Urban, Jennifer, MD ; King, Brett A., MD, PhD</creator><creatorcontrib>Levy, Lauren L., MD ; Urban, Jennifer, MD ; King, Brett A., MD, PhD</creatorcontrib><description>Background Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. Objective We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. Methods Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. Results Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 ( P < .05) during 8 to 29 weeks of treatment. There were no adverse events. Limitations Small sample size, lack of placebo control group, and the possibility of bias are limitations. Conclusion The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2015.06.045</identifier><identifier>PMID: 26194706</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Adolescent ; Adult ; atopic dermatitis ; Dermatitis, Atopic - diagnosis ; Dermatitis, Atopic - drug therapy ; Dermatology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Janus kinase inhibitor ; Janus Kinases - antagonists & inhibitors ; Male ; Middle Aged ; Piperidines - administration & dosage ; Pyrimidines - administration & dosage ; Pyrroles - administration & dosage ; Risk Assessment ; Sampling Studies ; Severity of Illness Index ; tofacitinib ; Treatment Outcome ; Young Adult</subject><ispartof>Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.395-399</ispartof><rights>2015</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-bf3db2709821be1aa5907b6e20f2253ab2c4857553b25ac6bdbde075b78b15c33</citedby><cites>FETCH-LOGICAL-c481t-bf3db2709821be1aa5907b6e20f2253ab2c4857553b25ac6bdbde075b78b15c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962215018514$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26194706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levy, Lauren L., MD</creatorcontrib><creatorcontrib>Urban, Jennifer, MD</creatorcontrib><creatorcontrib>King, Brett A., MD, PhD</creatorcontrib><title>Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Background Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. Objective We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. Methods Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. Results Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 ( P < .05) during 8 to 29 weeks of treatment. There were no adverse events. Limitations Small sample size, lack of placebo control group, and the possibility of bias are limitations. Conclusion The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>atopic dermatitis</subject><subject>Dermatitis, Atopic - diagnosis</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Janus kinase inhibitor</subject><subject>Janus Kinases - antagonists & inhibitors</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperidines - administration & dosage</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrroles - administration & dosage</subject><subject>Risk Assessment</subject><subject>Sampling Studies</subject><subject>Severity of Illness Index</subject><subject>tofacitinib</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhoMoznX0D7iQLN20nqRN0oIIMvjJgAvHdUjSU246bXNNUmX-val3dOHCVTjwvC_keQl5zqBmwOSrqZ6MGWoOTNQga2jFA3Jg0KtKqk49JAdgPVS95PyCPElpAoC-bdRjcsEl61sF8kCGm4gmL7hmGkYa0ZnZ-RxNuU0OJ-_ogHEx2Wef6E-fjzQfkYZoZvrZrFuit341Calfj976HCLNYTSlwq_e0t9VGZ-SR6OZEz67fy_Jt_fvbq4-VtdfPny6entdubZjubJjM1iuoO84s8iMET0oK5HDyLlojOWFE0qIxnJhnLSDHRCUsKqzTLimuSQvz72nGL5vmLJefHI4z2bFsCXNFIhWSSlVQfkZdTGkFHHUp-gXE-80A73b1ZPe7erdrgapi90SenHfv9kFh7-RPzoL8PoMYPnlD49RJ-dxdTj4ojbrIfj_97_5J-7m4rFscot3mKawxbX400wnrkF_3ffd52UCWCdY2_wClbihfg</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Levy, Lauren L., MD</creator><creator>Urban, Jennifer, MD</creator><creator>King, Brett A., MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate</title><author>Levy, Lauren L., MD ; Urban, Jennifer, MD ; King, Brett A., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-bf3db2709821be1aa5907b6e20f2253ab2c4857553b25ac6bdbde075b78b15c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>atopic dermatitis</topic><topic>Dermatitis, Atopic - diagnosis</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Janus kinase inhibitor</topic><topic>Janus Kinases - antagonists & inhibitors</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperidines - administration & dosage</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrroles - administration & dosage</topic><topic>Risk Assessment</topic><topic>Sampling Studies</topic><topic>Severity of Illness Index</topic><topic>tofacitinib</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levy, Lauren L., MD</creatorcontrib><creatorcontrib>Urban, Jennifer, MD</creatorcontrib><creatorcontrib>King, Brett A., MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levy, Lauren L., MD</au><au>Urban, Jennifer, MD</au><au>King, Brett A., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>73</volume><issue>3</issue><spage>395</spage><epage>399</epage><pages>395-399</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>Background Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. Objective We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. Methods Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. Results Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 ( P < .05) during 8 to 29 weeks of treatment. There were no adverse events. Limitations Small sample size, lack of placebo control group, and the possibility of bias are limitations. Conclusion The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26194706</pmid><doi>10.1016/j.jaad.2015.06.045</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.395-399 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1705476667 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Adolescent Adult atopic dermatitis Dermatitis, Atopic - diagnosis Dermatitis, Atopic - drug therapy Dermatology Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Humans Janus kinase inhibitor Janus Kinases - antagonists & inhibitors Male Middle Aged Piperidines - administration & dosage Pyrimidines - administration & dosage Pyrroles - administration & dosage Risk Assessment Sampling Studies Severity of Illness Index tofacitinib Treatment Outcome Young Adult |
| title | Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A47%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20recalcitrant%20atopic%20dermatitis%20with%20the%20oral%20Janus%20kinase%20inhibitor%20tofacitinib%20citrate&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Levy,%20Lauren%20L.,%20MD&rft.date=2015-09-01&rft.volume=73&rft.issue=3&rft.spage=395&rft.epage=399&rft.pages=395-399&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2015.06.045&rft_dat=%3Cproquest_cross%3E1705476667%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1705476667&rft_id=info:pmid/26194706&rft_els_id=S0190962215018514&rfr_iscdi=true |